OR WAIT null SECS
May 14, 2020
Santen Pharmaceutical has concluded a licensing agreement with jCyte for the development, registration, and commercialization rights to jCell, an investigational retinitis pigmentosa therapy, in Japan, Asia, and Europe.
May 13, 2020
The company will invest $180 million to construct a new 290,000-ft2 facility in Plainville, MA.
Hitachi Chemical Advanced Therapeutics Solutions and apceth Biopharma entered into long-term development and manufacturing services agreements for the clinical and commercial supply of multiple bluebird bio therapies.
Under the terms of the agreement, Catalent will develop a powder-in-capsule formulation of Ennaid’s ENU200 program at its site in San Diego, CA.
Through the agreement, Mylan will manufacture and distribute remdesivir in 127 low- and middle-income countries, including India.
In light of the current social distances measures, in place as a result of COVID-19, IMA Digital, part of IMA Group, has been providing virtual experiences for those interested in packaging and processing.
May 12, 2020
The companies have entered into a partnership to produce hydroxychloroquine, a treatment currently under investigation for COVID-19.
May 07, 2020
Boehringer Ingelheim will use the partnership to reveal novel insights into the complexities of various inflammatory diseases, which opens the potential for a clearer understanding of potential candidate biomarkers.
May 06, 2020
Quartic.ai and Bright Path Laboratories have agreed to develop an artificial intelligence (AI)-powered continuous manufacturing platform for APIs and other small-molecule drugs using Bright Path Labs’ continuous bioreactor and the Quartic.ai smart manufacturing technology.
CMO Evonik begins capacity expansion of APIs and intermediates at its sites in Dossenheim and Hanau Germany to increase EU supply security for drug products.